Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. - Test2 - elhamkhani - TriplyDB

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

http://www.wikidata.org/entity/Q33718837

about

Nonmyeloablative allogeneic hematopoietic cell transplantation Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction.The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation.Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.Cord-Blood Transplantation in Patients with Minimal Residual Disease Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation.Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation.Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial.Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.Donor and recipient sex in allogeneic stem cell transplantation: what really matters.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Patient selection for allogeneic hematopoietic cell transplantation (HCT): the evolution of HCT risk assessment.Reduced-intensity conditioned allogeneic SCT in adults with AML.Recent developments in HLA-haploidentical transplantations.Life after transplant: are we becoming high maintenance in AML?An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication.Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation Genetic stratification in myeloid diseases: from risk assessment to clinical decision support tool.Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians.Impact of early CMV reactivation in cord blood stem cell recipients in the current era.Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older.Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation.

P2860

Q26748780-28FD758F-D85B-4D63-9A68-102C4E1EA7AA Q30274960-B451A73A-5613-4149-87D4-52A83DB466F9 Q33429827-F8858621-733B-4185-BF4C-9C0F8F7F5D5E Q33438981-D43AB362-7090-4891-A0D8-244C7CE50557 Q33573495-738D9CA1-4CB0-4654-A406-5C733FFB5082 Q33766984-22E16282-8E41-4BD3-A4D1-378D9830DB12 Q33792160-6E9B9801-B16E-40EE-97B4-F826A0246078 Q33816022-96C4EFDA-32D6-4DAF-B92D-A7EEE99B25BA Q33847973-B3F3C135-05B4-4BCC-867C-468BE6C4ADA1 Q33911314-D485EF2C-3248-4210-AAA3-7CAB733F6DAF Q34325183-B53EFACE-77DB-4C25-9165-9BED5BDA7309 Q35583434-157C7904-1A29-4837-B28F-EBEB41240ACA Q35670693-B4FCD93B-ECBF-4E37-8E88-3883A1CAC424 Q35769347-E1128507-69F9-4576-A2AA-DA80F5655FDB Q35847466-35BCF5C5-03BB-4354-A38C-8F416CE58B1A Q35976578-3569119D-3ABF-4365-825F-5F4801488690 Q36090971-A4BCA6D8-58D1-441C-86FD-D5867A964DE7 Q36264895-05828A6B-716D-4C9B-A097-B4EB3C3053B9 Q36308832-9795B1B5-DB1F-4B35-9FC7-3339A5A7BA0C Q36445665-E95898BF-5152-45D1-8984-59D5CF73AE54 Q36445685-0207E9A9-1A88-4783-A4D0-C62E9CCD052F Q36596897-07991E95-7C12-4BE9-8F52-0B8E07F68847 Q36715911-378034E9-20A7-47C7-A526-0F543D67BD37 Q36724916-70DF61E8-E40E-4BAC-8609-B8782931DD3F Q37237916-7999D7EA-BB13-44E7-B282-C198E75A96CD Q37304130-71446E26-ECC1-44D3-8C3E-B19747D480A1 Q37624593-F80FD7F4-10C6-4D84-8506-6E48ADC0909A Q38287009-86574C04-9BB1-4A3B-B6BB-6C27FB9CCA8F Q38366632-A8A317E7-0E70-4883-AB28-81718BB1BA82 Q38641733-5218306D-6DB2-41A0-9689-065C6A477FB2 Q38801124-EA7D3C21-733F-4DF4-BB17-D8CF85413A48 Q38802147-414A2C83-2195-4A54-B0F7-A3D46A1E4907 Q38858092-FB99D64C-13DC-4D60-B993-55596DF633C1 Q38877336-99DFFBCC-8B5F-4D88-B98B-373507D6AC27 Q39100115-4DD88A7E-AE54-4D2B-9F9B-5B9794C5CE6A Q39116985-467B782D-0EA8-4154-9043-C1304B7FE7B2 Q39535615-021E586D-0446-43C8-B8DC-A17EC0D58404 Q39865680-1F81FD7A-951B-46BF-8FBF-AEE100CA88C3 Q39972636-0F6FC546-BD87-4780-81FD-2295EB51C182 Q40201370-C0970FBF-1020-4341-A186-D52D5FA19A66

P2860

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

http://www.wikidata.org/entity/Q33718837

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Validation and refinement of t ...... eic stem cell transplantation.

@ast

Validation and refinement of t ...... eic stem cell transplantation.

@en

type

label

Validation and refinement of t ...... eic stem cell transplantation.

@ast

Validation and refinement of t ...... eic stem cell transplantation.

@en

prefLabel

Validation and refinement of t ...... eic stem cell transplantation.

@ast

Validation and refinement of t ...... eic stem cell transplantation.

@en

P1433

Q33718837-71FEB39B-759C-42FF-8B5B-F3CCD1AD1753

P1476

Q33718837-BB1B07A4-363E-4481-8E8B-02500219BF12

P2093

Q33718837-0BA14F06-8DB3-432B-979D-59DD8DB3A697

Q33718837-114F06C2-D41E-4D7D-AD0B-5C5DD6DF468C

Q33718837-1AB01383-332D-4374-A307-130C76645776

Q33718837-2CF8F1EF-98B0-43BB-9B9C-ACAEA27A3EDB

Q33718837-41A9EAB9-7BF7-40FD-B7F1-511C91F2274F

Q33718837-8293562A-8244-4F85-BAAB-A58DDBE2FD11

Q33718837-93E7B60E-1969-4454-A16E-C68D63E6D476

Q33718837-BB914440-0654-4FFD-AFE7-DC537A540E86

Q33718837-BCD073F7-CACC-439D-87B3-7CAAD3C81CFB

Q33718837-D23E3B9A-3963-4C95-A9A9-D4C5AF55EEDE

P2860

Q33718837-2DD90CDB-DF0A-4DD9-8966-BC5EB4F55A9C

Q33718837-30F49D8B-875B-436D-8EB8-BF76D4DF21F4

Q33718837-36B356E8-5D96-4E7F-8FF8-EB8485F8C14F

Q33718837-4299079D-E85F-43A9-8EEC-C24E8BCEF867

Q33718837-5872B345-6483-411A-9DF5-24165FB803C9

Q33718837-633149CE-5D6D-48D6-BACE-742247BB038A

Q33718837-65DE0CF2-89CF-4913-8770-31CDD636C8A5

Q33718837-7198B8AD-2783-4F84-8AB9-5BB1793B79C6

Q33718837-9DCA52D4-A05F-4055-BD42-BA6B233BFE02

Q33718837-AB131BE1-6D82-4C9F-9893-119C7F6AB37B

P304

Q33718837-53B3717B-999C-4FBB-AE73-C825EF0FB824

P31

Q33718837-E8B2CAC2-3660-407E-A9A1-DBEDC81A416A

P356

Q33718837-BD1DD4CD-A9D2-4975-8B78-C82CC205CFD4

P407

Q33718837-67605E84-B6D3-4928-8F16-AE7657AE5CCE

P433

Q33718837-AE7A2B16-911A-4A9E-9197-9D7B77AAE042

P478

Q33718837-EA43C68A-CBAA-491C-A752-0611C49EB064

P577

Q33718837-2E24282A-E5EB-41B1-A4DD-60D6B97DD143

P5875

Q33718837-EBAFAD8C-A693-4DA0-AA7D-574F5F6C4A53

P698

Q33718837-B177FD00-3462-4CD1-A641-A1F10F39938D

P932

Q33718837-FBF7ACEA-2051-4579-B548-24BB2EC2F982

P356

BLOOD-2014-01-552984

P1433

P1476

Validation and refinement of t ...... eic stem cell transplantation.

@en

P2093

Brent R Logan

http://www.w3.org/2001/XMLSchema#string

Daniel J Weisdorf

http://www.w3.org/2001/XMLSchema#string

Edwin P Alyea

http://www.w3.org/2001/XMLSchema#string

Haesook T Kim

http://www.w3.org/2001/XMLSchema#string

J Douglas Rizzo

http://www.w3.org/2001/XMLSchema#string

Joseph H Antin

http://www.w3.org/2001/XMLSchema#string

Mary M Horowitz

http://www.w3.org/2001/XMLSchema#string

Matt E Kalaycio

http://www.w3.org/2001/XMLSchema#string

Philippe Armand

http://www.w3.org/2001/XMLSchema#string

Richard T Maziarz

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

International scoring system for evaluating prognosis in myelodysplastic syndromes

Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes

Reduced mortality after allogeneic hematopoietic-cell transplantation.

Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study

A disease risk index for patients undergoing allogeneic stem cell transplantation.

Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival.

Peripheral-blood stem cells versus bone marrow from unrelated donors

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.

Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.

P304

3664-3671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-01-552984

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261773062

http://www.w3.org/2001/XMLSchema#string

P698

24744269

http://www.w3.org/2001/XMLSchema#string

P932

4047501

http://www.w3.org/2001/XMLSchema#string